奥翔药业(603229.SH)前三季度净利润2.07亿元，同比下降9.59%

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 646 million yuan, representing a year-on-year decrease of 6.4% [1] - The net profit attributable to shareholders of the parent company was 207 million yuan, down 9.59% year-on-year [1] - The basic earnings per share stood at 0.25 yuan [1]